EDISON, N.J., Jan. 4, 2017 /PRNewswire/ -- ContraVir
Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company
focused on the development and commercialization of targeted
antiviral therapies, announced today that it will present at the
Biotech Showcase 2017 to be held January
9-11, 2016, at the Hilton San Francisco Union Square.
James Sapirstein, Chief Executive
Officer of ContraVir, will provide an overview of the Company's
business during his live presentation and will be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
Event:
|
|
Biotech Showcase
2017
|
Date:
|
|
Monday, January 9,
2017
|
Time:
|
|
10:00am (Pacific
Time)
|
Location:
|
|
Hilton, Room 8,
Ballroom level
|
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development
and commercialization of targeted antiviral therapies with a
specific focus on developing a potentially curative therapy for
hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action:
Tenofovir Exalidex™ (formerly CMX157), a highly potent analog of
the successful antiviral drug tenofovir currently in Phase 2a,
which has demonstrated the potential for low, once a day dosing
compared to Viread® and decreased systemic exposure,
thereby potentially reducing renal and bone side effects; and
CRV431, a next generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine ™ (formerly FV-100),
an orally available nucleoside analogue prodrug for the treatment
of herpes zoster, or shingles, in a Phase 3 clinical trial. In
addition to direct antiviral activity, Valnivudine™ has
demonstrated the potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia (PHN) in
a Phase 2 clinical study. For more information visit
www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664
Claire LaCagnina (media)
clacagnina@tiberend.com; (212) 375-2686
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/contravir-pharmaceuticals-to-present-at-biotech-showcase-2017-300385204.html
SOURCE ContraVir Pharmaceuticals